image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 0.2461
-3.83 %
$ 23.6 M
Market Cap
0.02
P/E
1. INTRINSIC VALUE

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.[ Read More ]

The intrinsic value of one BNGO stock under the base case scenario is HIDDEN Compared to the current market price of 0.246 USD, Bionano Genomics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BNGO

image
FINANCIALS
36.1 M REVENUE
29.90%
-215 M OPERATING INCOME
-63.44%
-232 M NET INCOME
-75.34%
-125 M OPERATING CASH FLOW
-0.29%
24.2 M INVESTING CASH FLOW
-70.81%
114 M FINANCING CASH FLOW
394.70%
6.07 M REVENUE
-21.85%
-43.9 M OPERATING INCOME
-157.97%
-44.2 M NET INCOME
-172.72%
-13.3 M OPERATING CASH FLOW
36.56%
-5.38 M INVESTING CASH FLOW
-18.77%
23.6 M FINANCING CASH FLOW
1292.92%
Balance Sheet Decomposition Bionano Genomics, Inc.
image
Current Assets 140 M
Cash & Short-Term Investments 102 M
Receivables 9.66 M
Other Current Assets 28.6 M
Non-Current Assets 74.3 M
Long-Term Investments 400 K
PP&E 32.5 M
Other Non-Current Assets 41.4 M
Current Liabilities 100 M
Accounts Payable 10.4 M
Short-Term Debt 72.2 M
Other Current Liabilities 17.4 M
Non-Current Liabilities 18.2 M
Long-Term Debt 7.18 M
Other Non-Current Liabilities 11 M
EFFICIENCY
Earnings Waterfall Bionano Genomics, Inc.
image
Revenue 36.1 M
Cost Of Revenue 26.6 M
Gross Profit 9.57 M
Operating Expenses 149 M
Operating Income -215 M
Other Expenses 17.2 M
Net Income -232 M
RATIOS
26.49% GROSS MARGIN
26.49%
-595.98% OPERATING MARGIN
-595.98%
-643.74% NET MARGIN
-643.74%
-241.78% ROE
-241.78%
-108.44% ROA
-108.44%
-129.73% ROIC
-129.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bionano Genomics, Inc.
image
Net Income -232 M
Depreciation & Amortization 13.9 M
Capital Expenditures -1.69 M
Stock-Based Compensation 15.2 M
Change in Working Capital -14.8 M
Others 86.7 M
Free Cash Flow -127 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bionano Genomics, Inc.
image
Wall Street analysts predict an average 1-year price target for BNGO of $1.88 , with forecasts ranging from a low of $1 to a high of $3.5 .
BNGO Lowest Price Target Wall Street Target
1 USD 306.34%
BNGO Average Price Target Wall Street Target
1.88 USD 661.89%
BNGO Highest Price Target Wall Street Target
3.5 USD 1322.19%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Bionano Genomics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jun 13, 2023
Bought 50 K USD
Mamuszka Hannah
Director
+ 65789
0.76 USD
1 year ago
May 16, 2023
Bought 9.64 K USD
Holmlin R. Erik
President and CEO
+ 15000
0.6426 USD
1 year ago
May 12, 2023
Bought 33.4 K USD
Stewart Christopher P.
Chief Financial Officer
+ 50000
0.6683 USD
2 years ago
Aug 15, 2022
Sell 72.4 K USD
Linney Yvonne
director:
- 20000
3.6201 USD
2 years ago
May 16, 2022
Bought 16 K USD
BARKER DAVID L
director:
+ 10000
1.6 USD
2 years ago
Nov 29, 2021
Bought 597 USD
Holmlin R. Erik
President and CEO
+ 150
3.98 USD
2 years ago
Nov 29, 2021
Bought 10.7 K USD
Holmlin R. Erik
President and CEO
+ 2675
3.99 USD
2 years ago
Nov 29, 2021
Bought 8.77 K USD
Holmlin R. Erik
President and CEO
+ 2200
3.985 USD
6 years ago
Aug 21, 2018
Bought 25.2 K USD
BARKER DAVID L
Director
+ 3894
6.47 USD
6 years ago
Aug 21, 2018
Bought 25.2 K USD
BARKER DAVID L
Director
+ 3894
6.47 USD
6 years ago
Aug 23, 2018
Bought 9.98 K USD
Holmlin R. Erik
President and CEO
+ 1630
6.125 USD
6 years ago
Aug 23, 2018
Bought 9.98 K USD
Holmlin R. Erik
President and CEO
+ 1630
6.125 USD
6 years ago
Aug 23, 2018
Bought 4.99 K USD
Borodkin Mark
Chief Operating Officer
+ 815
6.125 USD
6 years ago
Aug 23, 2018
Bought 4.99 K USD
Borodkin Mark
Chief Operating Officer
+ 815
6.125 USD
6 years ago
Aug 23, 2018
Bought 61.2 K USD
TWOMEY CHRISTOPHER J
Director
+ 10000
6.125 USD
6 years ago
Aug 23, 2018
Bought 61.2 K USD
TWOMEY CHRISTOPHER J
Director
+ 10000
6.125 USD
6 years ago
Aug 23, 2018
Bought 91.9 K USD
Domain Partners VIII, L.P.
10 percent owner
+ 15000
6.125 USD
6 years ago
Aug 23, 2018
Bought 91.9 K USD
Domain Partners VIII, L.P.
10 percent owner
+ 15000
6.125 USD
7. News
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Destiny Hance - Ladenburg Thalmann Mark Massaro - BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today's conference is being recorded. seekingalpha.com - 3 days ago
Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued clinical service products. Q3 2024 revenue represents a 35% decrease from Q3 2023 Total installed base of 368 optical genome mapping (OGM) systems as of Q3 2024, which represents a 22% increase over Q3 2023 Sold 7,835 nanochannel array flowcells in Q3 2024, which represents a 27% increase from the number of flowcells sold in Q3 2023 Conference call today, November 13, 2024 at 4:30 PM ET SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2024. globenewswire.com - 3 days ago
Optical Genome Mapping Market to Witness 26.76% CAGR During 2024-2030 - Consumables and Reagents to Register High Growth - Bionano Genomics, Nucleome Informatics, and Praxis Genomics Dominate the Industry Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Optical Genome Mapping Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global optical genome mapping market is estimated to reach USD 536.4 million by 2030. The market is projected to grow at a CAGR of 26.76% from 2024 to 2030. This can be attributed to developments in studying efficient treatments for a variety of chronic diseases. The ability of optical genome mapping (OGM) to complement other genomic sequencing technologies, such as next-generation sequencing (NGS), has created synergies in genomics research. globenewswire.com - 1 week ago
Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the “Warrants”) at a combined offering price of $0.3039 per share of common stock and accompanying Warrants. The Warrants have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”). The Series C warrants expire five years following the date of the Stockholder Approval and the short-term Series D warrants expire eighteen months following the date of Stockholder Approval. globenewswire.com - 2 weeks ago
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024 SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 and subsequently adjourned to October 30, 2024 (the “Special Meeting”) because a quorum was not present at the time of the reconvened meeting. Based on preliminary reports as of October 30, 2024, approximately 30.7% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total shares outstanding as of the record date are necessary to satisfy the quorum requirements for a meeting. globenewswire.com - 2 weeks ago
Bionano Announces Preliminary 3Q 2024 Revenues and Cash SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third quarter of 2024 to be between $6.5 and $6.8 million, down from prior guidance of between $7.9 and $8.9 million. globenewswire.com - 1 month ago
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 2 months ago
Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript) Bionano Genomics, Inc. (NASDAQ:BNGO ) Canaccord Genuity 44th Annual Growth Results Conference August 13, 2024 3:30 PM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Mikson Hi. Welcome to the Canaccord Genuity Global Growth Conference. seekingalpha.com - 3 months ago
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 nanochannel array flowcells in Q2 2024, which represents a 13% decrease from the number of flowcells sold in Q2 2023 The editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies Conference call today, August 7th, 2024 at 4:30 PM ET SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2024. “We saw positive growth in the OGM installed base this quarter, along with key advancements to our VIA software and the achievement of a significant milestone with the establishment of a Category I CPT code for OGM, which we believe will raise the awareness and utility of OGM,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano. globenewswire.com - 3 months ago
Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024. globenewswire.com - 3 months ago
Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants globenewswire.com - 4 months ago
8. Profile Summary

Bionano Genomics, Inc. BNGO

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 23.6 M
Dividend Yield 0.00%
Description Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Contact 9540 Towne Centre Drive, San Diego, CA, 92121 https://www.bionanogenomics.com
IPO Date Aug. 21, 2018
Employees 344
Officers Mr. Jonathan Dixon J.D. General Counsel & Secretary Dr. Robert Erik Holmlin M.B.A., Ph.D. President, Chief Executive Officer & Director and Chief Financial Officer Mr. Cory Kreeck Global Head of People Operations Ms. Donna Polizio Global Head of Market Access Mr. Stanislas Marin M.B.A., M.S. Vice President of Global Sales Mr. Mark Adamchak CPA Vice President of Accounting & Controller Mr. Mark Oldakowski Chief Operating Officer Dr. Alka Chaubey FACMG, Ph.D. Chief Medical Officer